|
| ncRNA | Sample resource(s) | Functions | Effect(s) | References |
|
| LINC00311 | OVX mice injected with LINC00311 intraperitoneally | Positive | Accelerates osteoclast growth, increases osteoclast numbers, promotes osteoclast proliferation, and inhibits osteoclast apoptosis | [101] |
| MAYA | MAYA-knockdown mice (by shRNA or locked nucleic acid) | Positive | Reduces bone lesions and breast cancer bone tumor burden | [136] |
| MALAT1 | Femur fracture mice treated with exosomes derived from EPCs transfected with MALAT1-targeting siRNA | Positive | Inhibits osteoclastogenesis and bone healing | [82] |
| circRNA_28313 | circRNA_28313-knockdown OVX mice (Lsh-circRNA_28313-infected) | Positive | Exhibits increased BV/TV, Tb.N, Tb.Th, and Tb.Sp | [29] |
| miR-21 | miR-21-knockout mice | Positive | Exhibits inhibited bone resorption, osteoclast differentiation and activity, and increased bone mass | [189, 198] |
| miR-214 | Osteoclastic miR-214 transgenic mice | Positive | Exhibits increased osteoclast activity and bone resorption and reduced bone mineral density (BMD) | [109, 192, 199] |
| mir-182 | (1) mir-182flox/floxLysMcre(+) mice
(2) mir-182+/+LysMcre(+) mice | Positive | Compared with (2), (1) exhibits increased bone mass, connectivity density, BV, BMD, and Tb.N and decreased trabecular bone spacing | [88] |
| miR-148a | Silencing of miR-148a with an antagomir | Positive | Inhibits bone resorption and increases bone mass | [124] |
| miR-9718 | Silencing of miR-9718 with an antagomir in OVX mice and sham-operated control mice | Positive | Exhibits inhibited bone resorption and increased bone mass in both OVX mice and sham-operated control mice | [127] |
| miR-145-5p | miR-145-5p agomir-treated collagen-induced arthritis (CIA) mice | Positive | Enhances bone erosion | [49] |
| miR-34a | (1) miR-34a-knockout and heterozygous mice
(2) Osteoclastic miR-34a transgenic mice | Negative | (1) Exhibits increased bone resorption and reduced bone mass
(2) Exhibits inhibited bone resorption and increased bone mass | [120] |
| miR-155 | miR-155-/- CIA mice | Negative | Exhibits reduced generation of osteoclasts and local bone destruction | [200] |
| miR-124 | (1) Adjuvant-induced arthritis mice treated with pre-miR-124
(2) Nude mice transplanted with MDA-MB-231 cells (breast cancer cell line) expressing miR-124 | Negative | (1) Exhibits reduced osteoclast numbers and activity and inhibited osteoclast differentiation
(2) Inhibits bone metastasis of breast cancer cells and cancer cell-induced osteolysis and shows relieved bone lesion | [37, 201] |
| miR-146a | CIA mice injected with miR-146a | Negative | Less osteoclasts at the border of the pannus and bone | [56] |
| miR-503 | (1) Silencing of miR-503 with and antagomir
(2) Overexpression of miR-503 with agomir | Negative | (1) Increases RANK protein expression and bone resorption and reduces bone mass
(2) Inhibits bone resorption and bone loss | [38] |
| miR-145 | Bilateral OVX-operated mice treated with a miR-145 agomir | Negative | Attenuates trabecular disconnection and separation and reverses the increase in the RANKL to OPG ratio | [60] |
| miR-17~92 | miR-17~92 osteoclast conditional knockout mice | Negative | Exhibits decreased connectivity density, BV/TV, BMD, Tb.N, and Tb.Th and increased trabecular separation and bone resorption | [155] |
| miR-141 | (1) Mice injected with pre-miR-141
(2) Nude mice inoculated with SCP28 cells via intracardiac injection and then injected with pre-miR-141
(3) Aged rhesus monkeys with miR-141 delivery into osteoclasts via a nucleic acid delivery system | Negative | ((1) and (2)) Exhibits decreased bone lesions, osteoclast numbers and activity, and breast cancer bone tumor burden
(3) Exhibits decreased bone erosion and osteoclast numbers and activity | [52, 55] |
| miR-219 | (1) Mice injected with pre-miR-219
(2) Nude mice inoculated with SCP28 cells via intracardiac injection and then injected with pre-miR-219 | Negative | ((1) and (2)) Exhibits decreased bone lesions, osteoclast numbers and activity, and breast cancer bone tumor burden | [55] |
| miR-190 | Mice injected with pre-miR-190 | Negative | Reduces osteoclast activity | [55] |
| miR-100-5p | OVX mice treated with agomir-miR-100-5p | Negative | Decreases osteoclast numbers and the expression of osteoclast-specific genes | [50] |
| miR-27a | OVX mice injected with miR-27a-carrying chitosan | Negative | Inhibits osteoclast differentiation and activity | [84] |
| miR-223 | CIA mice injected with lentiviral vectors expressing a miR-223 target sequence | Negative/positive | Exhibits decreased osteoclastogenesis, osteoclast numbers and bone erosion, and relatively intact bone | [202] |
| miR-133a | Spinal tuberculosis rabbit injected with notochordal cells containing miR-133a (1) mimic or (2) inhibitor
(3) Mice intravenously injected with pre-miRNA-133a
(4) miR-133a knockdown in OVX rats by injecting with antagomiR-133a | Negative/positive | (1) Exhibits reduced osteoclast numbers
(2) Opposite to (1)
(3) Reduces osteoclast activity
(4) Decreases bone erosion and levels of osteoclastogenesis-related factors in serum and increases lumbar spine BMD | [55, 92, 197] |
| miR-106b | CIA mice injected with (1) miR-106b mimics or (2) inhibitor
OVX mice injected with (3) agomiR-106b or (4) antagomiR-106b | ((1) and (2)) Positive
((3) and (4)) Negative | (1) Similar to NC
(2) Suppresses bone destruction and reduces osteoclast numbers and the RANKL/OPG ratio
(3) Increases BMD and other bone parameters and decreases osteoclast formation and activity
(4) Opposite to (3) | [41, 43] |
|
